Literature DB >> 28352136

Prostate cancer: Cabozantinib activates innate immunity.

Peter Sidaway.   

Abstract

Entities:  

Year:  2017        PMID： 28352136     DOI： 10.1038/nrurol.2017.50

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.

Authors:  Akash Patnaik; Kenneth D Swanson; Eva Csizmadia; Aniruddh Solanki; Natalie Landon-Brace; Marina P Gehring; Katja Helenius; Brian M Olson; Athalia R Pyzer; Lily C Wang; Olivier Elemento; Jesse Novak; Thomas B Thornley; John M Asara; Laleh Montaser; Joshua J Timmons; Todd M Morgan; Yugang Wang; Elena Levantini; John G Clohessy; Kathleen Kelly; Pier Paolo Pandolfi; Jacalyn M Rosenblatt; David E Avigan; Huihui Ye; Jeffrey M Karp; Sabina Signoretti; Steven P Balk; Lewis C Cantley
Journal:  Cancer Discov       Date:  2017-03-08       Impact factor: 39.397
  1 in total
  2 in total

1.  Modulation of cabozantinib efficacy by the prostate tumor microenvironment.

Authors:  Manisha Tripathi; Srinivas Nandana; Sandrine Billet; Karen A Cavassani; Rajeev Mishra; Leland W K Chung; Edwin M Posadas; Neil A Bhowmick
Journal:  Oncotarget       Date:  2017-09-23

Review 2.  Current perspectives on bone metastases in castrate-resistant prostate cancer.

Authors:  Christopher Logothetis; Michael J Morris; Robert Den; Robert E Coleman
Journal:  Cancer Metastasis Rev       Date:  2018-03       Impact factor: 9.264
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.